- Home
- RM vs INZY Comparison
RM vs INZY Comparison
Compare RM & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RM
- INZY
- Stock Information
- Founded
- RM 1987
- INZY 2015
- Country
- RM United States
- INZY United States
- Employees
- RM N/A
- INZY N/A
- Industry
- RM Finance: Consumer Services
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- RM Finance
- INZY Health Care
- Exchange
- RM Nasdaq
- INZY Nasdaq
- Market Cap
- RM 291.2M
- INZY 321.4M
- IPO Year
- RM 2012
- INZY 2020
- Fundamental
- Price
- RM $31.35
- INZY $4.10
- Analyst Decision
- RM Hold
- INZY Strong Buy
- Analyst Count
- RM 2
- INZY 7
- Target Price
- RM $33.00
- INZY $16.14
- AVG Volume (30 Days)
- RM 21.4K
- INZY 270.2K
- Earning Date
- RM 11-06-2024
- INZY 11-05-2024
- Dividend Yield
- RM 3.86%
- INZY N/A
- EPS Growth
- RM N/A
- INZY N/A
- EPS
- RM 2.41
- INZY N/A
- Revenue
- RM $558,158,000.00
- INZY N/A
- Revenue This Year
- RM $13.15
- INZY N/A
- Revenue Next Year
- RM $3.60
- INZY N/A
- P/E Ratio
- RM $12.90
- INZY N/A
- Revenue Growth
- RM 6.27
- INZY N/A
- 52 Week Low
- RM $20.50
- INZY $2.71
- 52 Week High
- RM $34.15
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- RM 51.98
- INZY 32.00
- Support Level
- RM $28.16
- INZY $4.02
- Resistance Level
- RM $33.30
- INZY $4.74
- Average True Range (ATR)
- RM 1.22
- INZY 0.30
- MACD
- RM 0.25
- INZY -0.08
- Stochastic Oscillator
- RM 51.95
- INZY 5.10
About RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.